NOW ENROLLING PHASE III sunRIZE TRIAL In the study of congenital hyperinsulinism

Learn More »
sunrize logo

Living With HI

We are dedicated to supporting those impacted by frequent hypoglycemia (low blood glucose) related to hyperinsulinism. As we advance RZ358 through clinical studies, we regularly interact with patient advocacy organizations around the world to support research and disease awareness. Our interaction with the community is a frequent reminder of the serious unmet patient need and the importance of developing therapies such as RZ358.


Learn More About Hyperinsulinism
Watch Video in: English | French | Spanish | German | Hebrew | Italian

Compassionate Use / Expanded Access / Early Access 

Compassionate Use, also referred to as an Expanded Access, Early Access Program or just EAP, is designed to make an investigational medical product available as early as possible to patients without therapeutic options. This happens when all potential ways to treat a condition have been exhausted or when patients are neither good candidates for approved therapies nor qualify for a clinical trial. EAPs enable these patients to access potentially helpful therapies that are still under investigation and not yet approved for their condition. Rezolute is committed to providing safe and effective therapies for patients and supports the need for EAPs.

Through our EAP, we aim to provide RZ358 to patients who have experienced its therapeutic benefit in our clinical studies and wish to continue their treatment post-trial. The EAP may also be available for those with serious or life-threatening conditions associated with elevated insulin levels causing frequent low blood sugar levels, that lack other therapeutic options. 

If you have questions about participating in our clinical trials or feel you may qualify for the RZ358 EAP, please discuss with your healthcare provider, or contact us at:

Patient Organizations

The organizations below—all founded by parents of children with congenital CHI—help connect patients and families living with congenital HI to education, research, clinical care, support services, and the broader congenital HI community. These are just a few of the organizations with whom Rezolute collaborates to inform our daily work.

Living With DME

Diabetic retinopathy (DR) affects approximately one third of adults with diabetes and is the leading cause of vision loss in the working age population. Diabetic Macular Edema (DME) is a severe vision-threatening complication of DR characterized by swelling of the retina and thickening of the macula, the part of the eye that is responsible for high-resolution vision, and is estimated to affect more than 1 million individuals in the US.


Corporate Sponsorship Available

Are you a non-profit patient advocacy group looking for sponsorship or financial assistance for important patient-facing programs? Click here for inquiries on Rezolute’s corporate sponsorship program.